Management
Dr. Michael Chin is a practicing medical doctor and scientist who is the inventor of recombinant tafazzin enzyme replacement therapeutics (rTERTs), as well as the founder and CEO of TransCellular Therapeutics. He is responsible for the scientific and medical direction of the company. He is also currently a faculty member of the Tufts University School of Medicine and Tufts Medical Center, where he holds the Title of Research Director for the Tufts Hypertrophic Cardiomyopathy Center and Research Institute. He has over 20 years of experience in caring for patients and in supervising an extramurally funded research group studying the molecular biology of the cardiovascular system. He received his M.D. and Ph.D. degrees from the University of Rochester, completed his Internal Medicine Residency at John Hopkins and his Cardiology training at Brigham and Women's Hospital, an affiliate of Harvard Medical School.
Mr. Craig Philips has nearly 30 years of pharmaceutical experience in the US and overseas with both big and small pharma companies. He has experience with development and commercialization of both small molecules and biologic agents in a variety of health sectors including: oncology and hematology, autoimmune diseases, cardiovascular disorders, antiviral, dermatology, allergy and others. Craig spent the early part of his career with Bristol Myers, and then held senior positions at both Schering Plough (now Merck), and Bayer Schering . Most recently, Craig was President at Cell Therapeutics, a company focused on the development and commercialization of new cancer therapies. Craig has broad industry experience and an extensive record in lifecycle management, commercializing new drugs and in both business development and partnership management. |